5th Advances in Heart Failure 2022

O foco central será a divulgação, em primeira mão, dos desenvolvimentos científicos mais recentes nesta área, nomeadamente, os apresentados no Congresso Europeu de Cardiologia.

Este encontro científico ganha o seu pleno significado pela participação de um extenso corpo docente, constituído pelos peritos mais relevantes na área da Insuficiência Cardíaca, provenientes de todos os pontos do país e coadjuvado por peritos internacionais da mais elevada craveira.

Estamos certos que a troca de informação e a discussão de ideias sobre a abordagem da Insuficiência Cardíaca contribuirá, em última instância, para uma melhoria significativa dos cuidados a prestar aos doentes com Insuficiência Cardíaca no nosso país.

Sejam, por isso, bem-vindos ao Advances in Heart Failure 2022!

Manhã | 09:00 – 14:00

Manhã | 09:00 – 14:00

Heart Failure with Preserved Ejection Fraction

09:00 – 09:15	Opening session Altamiro da Costa Pereira, José Silva-Cardoso, Elisabete Martins, Emília Moreira
09:20 – 10:05	Heart Failure with preserved, normal and supra-normal LVEF Chairs: Manuel Campelo; Luis Menezes Falcão 09:20 – 09:30 \| Definitions and an approach to pathophysiology Mário Santos 09:30 – 09:40 \| Diagnostic strategy Pedro Morais Sarmento 09:40 – 09:50 \| Prognosis Brenda Moura 09:50 – 10:05 \| Discussion Panel: Ana Oliveira Soares; Gonçalo Proença
10:10 – 10:55	Advances in HFpEF pathophysiology and new possible therapeutic targets Chair: Mónica Mendes Pedro, Marisa Peres 10:10 – 10:20 \| The relevance of pericardial fat Carlos Aguiar 10:20 – 10:30 \| The central role of atrial function in HFpEF Sofia Cabral 10:30 – 10:40 \| Skeletal muscle iron deficiency impact in HFpEF Rui Baptista 10:40 – 10:55 \| Discussion Panel: David Roque, Manuel Vaz da Silva
10:55 – 11:15	Coffee Break
11:15 – 12:00	Industry Session Boehringer-Ingelheim / Lilly Empagliflozin: Early and Foundational Therapy across the Heart Failure Spectrum João Pedro Ferreira
12:05 – 12:50	Imaging in HFpEF Chairs: Fausto Pinto, Filipe Macedo 12:05 – 12:15 \| Advanced echocardiography methods Mariana Paiva 12:15 – 12:25 \| Magnetic Resonance Imaging Nuno Bettencourt 12:25 – 12:35 \| Other imaging techniques: When and how to use Ana G. Almeida 12:35 – 12:50 \| Discussion Panel: Sofia Cabral, Regina Ribeiras
12h55-13h05	PORTHOS Study: Patient recruitment initiation Chair: José Silva-Cardoso Speakers: Cristina Gavina, Rui Baptista
13:05 – 14:00	Lunch Break

Tarde | 14:00 – 18:40

Tarde | 14:00 – 18:40

Heart Failure with Preserved Ejection Fraction

14:00 – 14:30	ESC vs ACC/AHA Guidelines. HFpEF treatment: where do we stand in 2022? Chairs: Cândida Fonseca, Joana Pimenta 14:00 – 14:10 \| HFpEF treatment in ESC Guidelines Paulo Maia Araújo 14:10 – 14:20 \| HFpEF treatment in ACC/AHA Guidelines João R. Agostinho 14:20 – 14:30 \| Discussion Panel: Irene Marques; Ana Neto
14:35 – 14:45	Iron deficiency detection and treatment in HF: a survey amongst Portuguese HF experts José Silva-Cardoso
14:50 – 15:35	HFpEF Treatment 2022: Highlights Chairs: Elisabete Martins, Nuno Lousada 14:50 – 15:00 \| MRAs Jorge Ferreira 15:00 – 15:10 \| Sacubitril/Valsartan João R. Agostinho 15:10 – 15:20 \| SGLT2-inhibitors John McMurray 15:20 – 15:35 \| Discussion Panel: Rui Baptista; Joana Pimenta
15:35 – 15:50	Coffee Break
15:50 – 16:35	Industry Session Pfizer Cardiac amyloidosis: Clinical practice critical issues to address in your Heart Failure patient Chair: José Silva-Cardoso Speakers: Omar Siddiqi; Carlos Aguiar Welcome and Introduction José Silva-Cardoso State of the art Omar Siddiqi A national perspective Carlos Aguiar Discussion: All Take home messages: José Silva-Cardoso
16:40 – 17:25	ATTR Amyloidosis Chairs: Alexandra Toste, Dulce Brito 16:40 – 16:50 \| When and how to screen ATTR Amyloidosis in HF patients ? Xavier Resende 16:50 – 17:00 \| The importance of staging and prognosis assessment in the Tafamidis era Patrícia Rodrigues 17:00 – 17:10 \| Aortic stenosis and ATTR amyloidosis: how to manage the frequent duo in elderly patients? Elisabete Martins 17:10 – 17:25 \| Discussion Panel: Mariana Vasconcelos; Ana Rita Almeida
17:30 – 18:15	Management of Hypertrophic Cardiomyopathy: What’s new? Chairs: Hugo Madeira; Nuno Cardim 17:30 – 17:40 \| Cardiembolic risk: Do we need more scoring or longer monitoring? Alexandra Sousa 17:40 – 17:50 \| Mavacamten in HF stage C patients Luis Lopes 17:50 – 18:00 \|ICD recommendation: a critical appraisal of the American and European Guidelines Sérgio Barra 18:00 – 18:15 \| Discussion Panel: Luis Adão; António Fiarresga
18:20 – 18:40	Mini Industry Session Abbott The role of remote monitoring in patients with HFpEP: Evidence from CardioMems experience Speaker: Tiago Pereira da Silva

Manhã | 09:00 – 14:15

Manhã | 09:00 – 14:15

Heart Failure with Preserved Ejection Fraction

09:00-09:20	Cell Therapy in Heart Failure Chair: Lino Gonçalves Speaker: Diana Nascimento
09:25 – 10:10	Industry Session Vifor Pharma Serum potassium control during RAASi optimization – from scientific evidence to clinical practice Chair: Cândida Fonseca Speaker: José Silva-Cardoso, Irene Marques Welcome and introduction Cândida Fonseca Hyperkalemia as a limiting factor for neurohormonal blockade/modulation in clinical practice José Silva-Cardoso Clinical case: Serum potassium control for RAASi optimization in HF Irene Marques Discussion: All Conclusions and adjourn: Cândida Fonseca
10:15 – 10:35	The c-GMP pathway: the lunar side of Heart Failure Chair: Armando Mansilha Speaker: José Silva-Cardoso
10:35 – 10:50	Coffee Break
10:50 – 11:35	Industry Session Servier Sacubitril/Valsartan: From Guidelines to Clinical Practice Chair: José Silva-Cardoso Speakers: Carlos Aguiar, Alexandra Sousa, Filipa Almeida Guidelines AHA 2022 Carlos Aguiar Critical clinical practice issues: challenges and opportunities (eg HF – NYHA class II) and challenges (Hk, hypotension, comorbidities; drug costs vs hospitalization costs; balance for NHS Alexandra Sousa, Filipa Almeida
11:40 – 12:25	New approaches to acute and worsening Heart Failure Chairs: Aurora Andrade, Adelino Leite-Moreira 11:40 – 11:50 \| Early ambulatory detection and intervention (The CHAMPION trial) (champion strategy; telemonitorização e opt da Re congestiva) Roberto Pinto 11:50 – 12:00 \| Early in-hospital intervention: converting a threat into an opportunity (The TRANSITION, EMPULSE and AFFIRM-AHF Trials) Cristina Gavina 12:00 – 12:10 \| Early post-discharge intervention: the vulnerable phase intervention (The VICTORIA Trial) Sara Gonçalves 12:10 – 12:25 \| The Galactic-HF: a new perspective for worsening Heart Failure Cândida Fonseca Discussion Panel: Marta Braga; Inês Araújo
12:30 – 13:15	Industry Session Bayer The Cardiorenal Future Starts Now: Vericiguat and Finerenone Chair: José Silva-Cardoso Welcome and introduction José Silva Cardoso The Bayer Commitment to Cardio-Renal Research Isabel Fonseca Santos The concept of Worsening Heart Failure José Silva-Cardoso Vericiguat; a novel Heart Failure therapeutic pathway Gilles Dekeulenaer Discussion: all
13:15 – 14:15	Lunch Break

Tarde | 14:15 – 18:25

Tarde | 14:15 – 18:25

Heart Failure with Preserved Ejection Fraction

14:15 – 15:00	Industry Session Novartis Can we change the outlook for patients with HFrEF? Chair: José Silva-Cardoso Speakers: José Silva-Cardoso, Marta Nogueira
15:05 – 15:50	Rhythm control in HF Chairs: João Morais; Jorge Ferreira 15:05 – 15:15 \| Atrial fibrillation rhythm control: New insights from EAST-HFNET.AF and RAFT-HF João Primo 15:15 – 15:25 \| Ventricular Tachycardia Ablation: PARTITA trial – a Game changer? Pedro Adragão 15:25 – 15:35 \| The 2022 ESC Ventricular Arrhythmias and SCD Guidelines: echoes from the ESC Congress Ana Lebreiro 15:35 – 15:50 \| Discussion Panel: Filipa Almeida; Marta Nogueira
15:55 – 16:40	Industry Session Abbott Moving Forward in HF Management: recent advances and evidence in breaktrough devices Chair: Paulo Pinho Speakers: Marta Tavares da Silva; Carlos Aguiar Mitraclip Marta Tavares da Silva Tendyne Marta Tavares da Silva HeartMate3 Carlos Aguiar
16:40 – 16:55	Coffee Break
16:55 – 17:40	Advanced HF – Heart Transplantation. Overcoming donor organs shortage Chairs: Victor Gil, Elisabete Martins 16:55 – 17:05 \| Improving organ procurement organization in Portugal Fátima Franco 17:05 – 17:15 \| Organ donation after circulatory death Sandra Amorim 17:15 – 17:25 \|Transgenic organs and Xenotransplantation: the future? Carlos Aguiar 17:25 – 17:40 \| Discussion Panel: Rui Ferreira; Doroteia Silva
17:45 – 18:15	Heart Failure: Beyond Ejection Fraction Chair: José Silva-Cardoso Speaker: Javed Butler
18:20 – 18:25	Meeting Closure José Silva-Cardoso; Elisabete Martins; Emília Moreira